ClinicalTrials.govpublic full text
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
advanced solid tumors, selected solid tumors, bkm120, mek162, ras raf mutations, triple negative breast cancer, pancreatic cancer, ovarian cancer, nsclc progressed on egfr tki, pi3k inhibitor, mek inhibitor, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1032968
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.